Eurofins Celebrates 35 Years of Testing for Life and 25 Years as Best Performing Share Listed in Europe
27 October 2022 - 4:15PM
Business Wire
October marks the 35th anniversary of Eurofins (Paris:ERF).
Today, the global leader in bio-analysis with 61,000 staff across a
network of 940 laboratories in 59 countries, Eurofins’ growth has
been characterised by its steadfast focus on long-term value
creation for customers, employees and shareholders. Eurofins
companies have consistently invested in research and development,
start-up laboratories, acquisitions, physical infrastructure and IT
solutions, as part of their commitment to innovating for customers
and achieving scale and scientific leadership in laboratory
activities that have a direct positive impact on health and the
environment.
October also marks 25 years since the initial public offering
(IPO) of Eurofins Scientific on the Paris stock exchange on 24th
October 1997. According to a commissioned study, since its IPO,
Eurofins has delivered a remarkable total shareholder return
(reflecting share price appreciation and reinvestment of dividends)
of around 36,600%. Among all companies with listings in major
European exchanges over the 25 year time span, Eurofins ranks
highest in terms of total shareholder return, according to the
research firm. A hypothetical investment of around €2,700 in
Eurofins at the time of its IPO, plus the reinvestment of
dividends, would be worth about €1 million today.
Dr Gilles Martin, CEO and Founder, Eurofins: “As we
celebrate this milestone, I would like to extend a heartfelt thanks
to our global workforce for their commitment and efforts and to the
clients of all Eurofins companies for their trust. We will continue
to refine our service offering and significantly invest in and
strengthen our network. Through focussed investments in our unique
laboratory network and IT solutions, R&D, acquisitions and
organic growth, we intend to continue to improve and extend our
capabilities to offer the best and most innovative testing services
to our clients, while creating further opportunities for our
employees and shareholders.”
To mark this anniversary, Eurofins has developed a book charting
its development, growth and innovations over the past three
decades.
Further information available here.
About Eurofins– the global leader in bio-analysis
Eurofins is Testing for Life. With 61,000 staff across a network of
940 laboratories in 59 countries, Eurofins’ companies offer a
portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221026005852/en/
Investor Relations Eurofins Scientific SE +32 2 766 1620
ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024